Birgit E. P. J. Vriens

950 citations

39 papers · 584 indexed · h-index 11

Co-authors: Vivianne C. G. Tjan‐Heijnen P. J. van Diest Carolien H. M. van Deurzen Elsken van der Wall Evelyn M. Monninkhof Maaike de Boer Robert J. Brummer Michiel A. van Nieuwenhoven
Topics: Breast Cancer Treatment Studies (25 papers)HER2/EGFR in Cancer Research (13 papers)Advanced Breast Cancer Therapies (12 papers)
Cited by: Cancer Research Pathology and Forensic Medicine Oncology
Journals: Journal of Clinical Oncology PLoS ONE Cancer Research
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Birgit E. P. J. Vriens

37 papers receiving 571 citations

Peers

Countries citing papers authored by Birgit E. P. J. Vriens

Since Specialization

Citations

This map shows the geographic impact of Birgit E. P. J. Vriens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit E. P. J. Vriens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit E. P. J. Vriens more than expected).

Fields of papers citing papers by Birgit E. P. J. Vriens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit E. P. J. Vriens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit E. P. J. Vriens. The network helps show where Birgit E. P. J. Vriens may publish in the future.

Co-authorship network of co-authors of Birgit E. P. J. Vriens

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit E. P. J. Vriens. A scholar is included among the top collaborators of Birgit E. P. J. Vriens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit E. P. J. Vriens. Birgit E. P. J. Vriens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study 2025 ·The Breast ·(unknown),(unknown),Sandra M. E. Geurts,Jolien Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. Wouter Dercksen,Franchette van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen,Maaike de Boer	0
2	202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study 2024 ·ESMO Open ·(unknown),Sandra M. E. Geurts,J. Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. W. Dercksen,F. Van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),V.C.G. Tjan-Heijnen,Maaike de Boer	1
3	The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown),(unknown),Ingeborg J. H. Vriens,(unknown),Sanne Engelen,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen	4
4	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry 2023 ·The Lancet Regional Health - Europe ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	15
5	Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry 2023 ·Clinical Breast Cancer ·(unknown),Sandra M. E. Geurts,(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,(unknown),M. Wouter Dercksen,Manon J. Pepels,Natascha A. J. B. Peters,(unknown),Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	1
6	Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown),Sandra M. E. Geurts,(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,M. Wouter Dercksen,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,(unknown),Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	7
7	233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry 2023 ·ESMO Open ·Sandra M. E. Geurts,(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,J. Tol,Birgit E. P. J. Vriens,(unknown),(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,A. van de Wouw,(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
8	Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy 2022 ·npj Breast Cancer ·Romy Aarnoutse,Janine Ziemons,(unknown),Judith de Vos‐Geelen,Maaike de Boer,(unknown),Birgit E. P. J. Vriens,(unknown),Agnès J. van de Wouw,Ngoc Giang Le,Koen Venema,Sander S. Rensen,John Penders,Marjolein L. Smidt	28
9	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry 2021 ·International Journal of Cancer ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	10
10	Bereaved relatives’ quality of life before and during the COVID-19 pandemic: Results of the prospective, multicenter, observational eQuiPe study 2021 ·Palliative Medicine ·(unknown),Heidi P. Fransen,Ben van den Borne,Mathijs P. Hendriks,Hanneke W. M. van Laarhoven,(unknown),Natasja Raijmakers,Janneke van Roij,Dirkje W. Sommeijer,Birgit E. P. J. Vriens,Lia van Zuylen,Lonneke V. Franse	6
11	Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls 2021 ·Cancers ·Romy Aarnoutse,(unknown),Janine Ziemons,Judith de Vos‐Geelen,Maaike de Boer,(unknown),Birgit E. P. J. Vriens,Yvonne van Riet,(unknown),Agnès J. van de Wouw,Ngoc Giang Le,Koen Venema,Sander S. Rensen,John Penders,Marjolein L. Smidt	28
12	Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands 2021 ·Value in Health ·P. Schneider,Bram Ramaekers,Xavier Pouwels,Sandra M. E. Geurts,(unknown),Maaike de Boer,Birgit E. P. J. Vriens,(unknown),(unknown),Manon J. Pepels,Vivianne C. G. Tjan‐Heijnen,Manuela Joore	6
13	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. 2019 ·The Breast ·(unknown),Sandra M. E. Geurts,(unknown),Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,(unknown),D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
14	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) 2019 ·Breast Cancer Research ·Stefanie de Groot,Hanno Pijl,Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Hein Putter,Marta Fiocco,Gerrit‐Jan Liefers,Jacobus J. M. van der Hoeven,J.W.R. Nortier,Judith R. Kroep	7
15	The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study 2018 ·European Journal of Surgical Oncology ·(unknown),(unknown),Guusje Vugts,Thijs van Dalen,(unknown),Birgit E. P. J. Vriens,Grard A. P. Nieuwenhuijzen,Robert‐Jan Schipper	4
16	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) 2014 ·Annals of Oncology ·Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,N.A.T. Hamdy,Hein Putter,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,E. Maartense,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Martin N.J.M. Wasser,A. Elise van Leeuwen‐Stok,Gerrit‐Jan Liefers,C.J.H. van de Velde,J. W. R. Nortier,Judith R. Kroep	31
17	Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 2013 ·European Journal of Cancer ·Birgit E. P. J. Vriens,Maureen J.B. Aarts,Bart de Vries,(unknown),J. Wals,Tineke J. Smilde,L.J.C. van Warmerdam,Maaike de Boer,D.J. van Spronsen,George F. Borm,Vivianne C. G. Tjan‐Heijnen	31
18	Taxane resistance in breast cancer: A closed HER2 circuit? 2012 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·(unknown),Jürgen Veeck,Birgit E. P. J. Vriens,(unknown),Manon van Engeland,Vivianne C. G. Tjan‐Heijnen	32
19	Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review 2009 ·European Journal of Cancer ·Carolien H. M. van Deurzen,Birgit E. P. J. Vriens,Vivianne C. G. Tjan‐Heijnen,Elsken van der Wall,(unknown),(unknown),Evelyn M. Monninkhof,P. J. van Diest	141
20	Effect of dehydration on gastrointestinal function at rest and during exercise in humans 2000 ·European Journal of Applied Physiology ·Michiel A. van Nieuwenhoven,Birgit E. P. J. Vriens,Robert J. Brummer,Fred Brouns	58

About Birgit E. P. J. Vriens

Birgit E. P. J. Vriens is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 39 papers that have together received 584 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (25 papers), HER2/EGFR in Cancer Research (13 papers) and Advanced Breast Cancer Therapies (12 papers). The work is most often cited by research in Cancer Research (281 citations), Pathology and Forensic Medicine (181 citations) and Oncology (220 citations). Birgit E. P. J. Vriens has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Vivianne C. G. Tjan‐Heijnen, P. J. van Diest, Carolien H. M. van Deurzen, Elsken van der Wall, Evelyn M. Monninkhof, Maaike de Boer, Robert J. Brummer, Michiel A. van Nieuwenhoven, Fred Brouns and L.J.C. van Warmerdam. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact